MINNEAPOLIS, MN–(Marketwire – August 31, 2010) –  Sunshine Heart Inc., a global medical device company focused on innovative technologies for moderate heart failure, today announced that its C-Pulse^® Heart Assist System has been successfully implanted using a minimally invasive thoracotomy procedure at Saint Luke’s Mid America Heart and Vascular Institute in Kansas City, MO. The C-Pulse System is the first known mechanical heart assist system to be implanted using a minimally invasive thoracotomy technique. The device was inserted through a small, pacemaker-like incision between the patient’s ribs, leaving the sternum intact. To date, thirteen patients have been implanted under Sunshine Heart’s existing worldwide C-Pulse study protocols. The FDA approved IDE feasibility study will include a total of 20 patients to evaluate the performance of this device for patients with moderate heart failure.

The C-Pulse Heart Assist System is designed to treat patients suffering from the debilitating effects of moderate heart failure caused by a failing left ventricle (the left heart chamber). The C-Pulse System features a unique balloon counterpulsation technology that is designed to assist the left ventricle by reducing the workload required to pump blood throughout the body. In addition, it increases blood flow to the coronary arteries. Combined, these potential benefits may help reverse the heart failure process or maintain the patient’s current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. 

“We are pleased to welcome Saint Luke’s Mid America Heart and Vascular Institute to our C-Pulse clinical trial,” said Dave Rosa, CEO of Sunshine Heart. “These latest procedures accomplish our goal of successfully implanting the C-Pulse System through a mini-thoracotomy surgical method. As we approach the end of our feasibility study, we are encouraged by the interest of our centers and we remain dedicated to developing this minimally invasive, cost-effective treatment that is intended to relieve the symptoms of moderate heart failure.”

Sanjeev Aggarwal, MD, Director of Mechanical Circulatory Support at Saint Luke’s Mid America Heart and Vascular Institute in Kansas City, Missouri, performed the procedures. In addition to performing the first minimally invasive thoracotomy C-Pulse procedures, Dr. Aggarwal has also successfully performed a minimally invasive hemi-sternotomy (mini-sternotomy) C-Pulse procedure at St. Luke’s Hospital.

“The C-Pulse Heart Assist System represents an important advance in the treatment of patients suffering from heart failure,” commented Dr. Aggarwal. “In our initial procedure last month, the clinical effects were dramatic, with an almost immediate improvement in cardiac performance and the patient’s functional status. I am very encouraged that we were able to perform our two subsequent implants utilizing a minimally invasive pacemaker-like incision, without dividing the sternum. This offers the opportunity to provide patients suffering from moderate heart failure with a means of mechanical circulatory support through a truly minimally invasive, low risk procedure with a short recovery period.”

“Today, there are few treatment options for the millions of Class III/IVa moderate heart failure patients who have achieved the maximum benefits of drug and pacemaker therapy yet still suffer from symptoms such as shortness of breath and reduced mobility,” said Dr. Andrew Kao, Medical Director of Heart Transplantation at St. Luke’s Mid America Heart Institute. “I am very pleased that the new C-Pulse therapy is being studied at St. Luke’s Hospital as we believe this device can make a tremendous difference for these patients who have limited treatment options.”

The C-Pulse System is an earlier intervention than other mechanical therapies, such as LVADs. This device does not make direct contact with patient’s blood and it can be turned on or off at any time allowing patients intervals of freedom to perform certain activities. The C-Pulse System can also be implanted as a minimally invasive procedure, thereby potentially reducing procedural time, hospital stays, overall cost and patient risk as compared to a traditional sternotomy.

Sunshine Heart’s FDA approved IDE study is available to men and women between the ages of 18 to 75 who suffer from Class III/ambulatory Class IV heart failure and for whom standard drug therapy has failed. The study monitors each patient’s performance with the C-Pulse System at one-month, three-month and six-month intervals to assess risks and potential benefits. Each patient’s physical endurance, quality of life and cardiac performance will also be specifically monitored.

About the C-Pulse Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously.

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sensing lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and electrical leads are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices that reside or function in the bloodstream.

About Sunshine Heart
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative technologies for the treatment of moderate heart failure, is commercializing the C-Pulse^® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. The C-Pulse System relieves the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20-patient U.S. clinical trial with the C-Pulse^® System and the study has achieved more than fifty percent enrollment as of August 2010. Sunshine Heart, Inc. is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.

Click here to see all recent news from this company

CALGARY, ALBERTA–(Marketwire – Aug. 31, 2010) – This Saturday, Recovery Acres (Calgary) Society and Moscow Ballet will host open auditions for Swan Lake on Saturday, September 4, 9:00AM at Ballet Classique, 176 Bedford Drive NE. The accepted applicants will perform on November 22 & 23 in Moscow Ballet’s Great Russian Swan Lake at 7:30PM, at the EPCOR CENTRE’S Jack Singer Concert Hall.

Swan Lake auditions are for pre-professional ballet students, ages thirteen to sixteen with pointe experience. Twelve applicants will be chosen to dance in one scene of Swan Lake with the 40-strong professional, Russian trained cast. Applicants must dress in dance attire and be prepared to dance en pointe. For local information, contact Sara Lynne Dewer at (403) 245 4346.

Nataliya Miroshnyk, a Russian trained soloist with Moscow Ballet, will conduct the audition and work with the selected students in rehearsal at a later date. During her audition tour, she will work one-on-one with young dancers in Calgary, Medicine Hat, Regina, Saskatoon, Surrey, Winnipeg and Thunder Bay. Nataliya, a graduate from the well-respected Kiev Academic Choreographic School in Ukraine, trained under the honoured A.G. Kalchenko.

“Having Nataliya lead auditions is both exciting and inspirational,” says Sara Lynne Dewer, Ballet Classique’s director. “Not only does she expose dancers to authentic Russian form, but this opportunity epitomizes inclusive artistic collaboration – providing a flavour of local, amateur energy in this production, is a true gift for these children, and for audiences.”

The Moscow Ballet Canadian tour is presented by Recovery Acres (Calgary) Society, one of Canada’s most effective, non-profit, addiction treatment facilities. A portion of tour proceeds will support capital funding for the facility’s needed $10M expansion project.

As one of the most revered ballets in the world, Swan Lake premiered over a century ago in Russia and remains a timeless classic, expressing a range of human emotions accented by Tchaikovsky’s luminous score.

Ticket prices range from $45-$140 and are now available through www.epcorcentre.org.

To view promotional reel, please visit: Great Russian Swan Lake.

For more information on the Moscow Ballet Canadian Tour, please visit www.moscowballetcanada.com.

About Nataliya Miroshnyk – Visiting Ballet Mistress

Nataliya enjoyed a tremendous amount of post-graduate experience throughout the world during her time with the Odessa State Academic Opera and Ballet Theatre. She was with the Company for almost twelve years and traveled to many countries including China, Japan, Germany, Lebanon and Finland. 

Nataliya also worked with La Classique, a well-known classical ballet troupe based in Moscow. Working with La Classique gave her the opportunity to perform in front of new audiences throughout the United Kingdom, Italy and Norway.

About Moscow Ballet – The Company

Moscow Ballet (est. 1993) is a Massachusetts-based touring company, whose roster features graduates of Perm, Yaganova, Moscow State Academic Choreographic and Kiev schools from Russia each year. Created by award-winning theatrical producer and Juilliard alumni, Akiva Talmi, the company tours upwards of 70 US cities per year, recently branching into a growing number of Canadian cities.

Through the Moscow Ballet’s Educational Outreach Program, “Celebrating Children: The Arts Can Make a Difference”, the company engages local children to audition and appear with professional dancers in the roles of cygnets, snowflakes and butterflies. www.nutcracker.com.

About Recovery Acres (Calgary) Society – Tour presenter & beneficiary

In partnership with the Moscow Ballet, Calgary-based Recovery Acres Society is raising $10 million dollars of capital funding to build a new alcohol and drug treatment facility for men. Once complete, the current building will be renovated to accommodate female clients. Wait lists are ever growing and the need, particularly for woman, is consistently on the rise.

Recovery Acres (Calgary) Society is a North American leader in the treatment of alcohol and drug addiction. Their proven Recovery Model serves as a best practices model for treatment facilities and clients from around the world. The affordability of its program opens the reality of rehabilitation to a broad spectrum of clientele. www.recoveryacres.org.

TUSTIN, CA–(Marketwire – August 31, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC’s US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.

Over 1,000 colorectal patient samples with various disease stages will be tested in parallel by RPC and Mayo Clinic to directly compare the results of the Onko-Sure® test with the Carcinoembryonic Antigen (CEA) test. The primary goal of the study is to determine whether Onko-Sure® is more effective than CEA at detecting early stage colorectal cancers. CEA has been reported to misdiagnose a disproportionate number of early stage cancers. Detecting cancer in earlier stages can lead to improved accuracy in the treatment, monitoring and recurrence monitoring of the disease in cancer patients. This head-to-head study is scheduled to be completed in the fourth quarter FY2010 and data generated will be provided to Mayo physicians and investigators for publication in medical journals.

“We are very excited to resume collaboration with Mayo’s Validation Support Services team. This marks a critical and potentially market changing milestone for Radient Pharmaceuticals and for our Onko-Sure® IVD cancer test,” commented Douglas MacLellan, Chairman and CEO of RPC. “Through this work, we expect to validate the efficacy of RPC’s Onko-Sure® test as a critical tool for treatment, monitoring, and/or recurrence monitoring of colorectal cancer suffers.”

RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Mayo Validation Support Services:
Mayo Validation Support Services, an affiliate of Mayo Clinic, based in Rochester, Minnesota and assists pharmaceutical, biotechnology and diagnostic companies in validating the clinical significance of emerging biomarkers and technologies. Mayo’s contribution of well-annotated biospecimens and clinical follow-up data support the development of individualized medicine, one of Mayo’s strategic initiatives.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

HILO, HI–(Marketwire – August 31, 2010) – –Pacific Quest, a unique, internationally recognized wilderness therapy program for struggling teens and young adults, located on the Big Island of Hawaii, is pleased to announce the launch of their new website http://www.pacificquest.org.

Mike McKinney, Co-Founder and Executive Director of Pacific Quest, commented, “We’re very pleased with the look and feel of the site… the new site demonstrates how far we have come in a short amount of time — from an emerging program with bold ideas in 2004, to today, one of the most innovative and respected wilderness programs in the industry.”

Notable features on the newly updated website include:

• Richer Content — Enhanced internal pages, including updated information on the Program, Health and Wellness, Clinical Services, and Admissions
• Social Media — Stay connected with Pacific Quest through their blog, Facebook or Twitter pages
• Expanded Media Library — See the wilderness therapy programs close up with more pictures and videos
• Improved Navigation — Move more easily through the site to find what you are looking for
• CMS — A new content management system allows for updates to the site in real time 

Mark Agosto, Outreach Director, added, “We hope the new website can be an effective resource for teens and young adults, and their families, as well as with our network of professionals. We are thrilled to share a little bit more about Pacific Quest with the community.”

For more information regarding Pacific Quest, please visit www.pacificquest.org or contact Mark Agosto, Outreach Director, at (808) 937-5806 or via email at [email protected].

To read more on this topic, visit: http://www.pacificquest.org/news/1/196/Pacific-Quest-Wilderness-Therapy-Program-Announces-New-Website/.

About Pacific Quest:

Pacific Quest is an outdoor behavioral healthcare (“wilderness therapy”) and sustainable treatment program for struggling teens and young adults, located on the Big Island of Hawaii. The program offers a clinical, yet holistic approach to treatment — going beyond traditional therapy and teaching sustainable life skills. Owned and operated by a veteran team of professionals with over 200 years of combined program experience, Pacific Quest offers a unique approach to treatment that is individualized for each student. Through experiential education, clinical services, a dedicated approach to health and wellness, and sustainable gardening, Pacific Quest provides a structured yet flexible outdoor therapy environment that serves the individual needs of each student, cultivating a therapy experience with personal meaning and importance.

Click here to see all recent news from this company

GLOSTRUP, DENMARK–(Marketwire – August 31, 2010) – Dako, a leading player in the field of advanced staining, launches a new staining solution for H&E. The pathology laboratories today are facing many constraining factors; finding and retaining trained laboratory staff is more difficult, and the need for more efficient and cost effective solutions is essential. Dako has designed a new H&E solution to meet the needs of the customer. Today Dako is launching the CoverStainer helping to optimize the laboratory process and delivering high quality, consistent results.

“At Dako, it all starts out with quality. We have transformed all our knowledge within IHC and Special Stains into the H&E area. We have done this not just by focusing on the instrument like many of our competitors do, but we have taken it one step further and are providing a full solution with reagents and instrumentation that work together perfectly. First we standardize and then we automate to secure quality at every step,” Lars Holmkvist, Dako’s CEO, says. He continues: “We are trying to help the laboratory with the most efficient means, so they can control the lab at the highest level of quality, and deliver fast answers to the patients.”

What is H&E staining?
When a patient is confronted with a possible cancer diagnosis, a biopsy is performed and a tissue specimen is taken. The specimen is tested in a pathology laboratory, using a process referred to as Hematoxylin and Eosin or H&E staining. The H&E stain is the first stain in the diagnostic process where a pathologist confirms or rules out a possible disease. The patient will either be able to go home with a ‘normal’ result, or they will be told that more confirmatory testing is required. A majority of the H&E samples can be diagnosed immediately. The pathologist can confirm or rule out a cancer diagnosis.

Prof. Dr. Hermann Herbst at Vivantes in Berlin, Germany has been using the Dako CoverStainer for four months in their routine operations, shares his findings: “You want to have a standardized process. At Vivantes we did a test of around 3000 slides, and our measurements show that the Dako CoverStainer saves us about 43% of the time needed in the older procedure. Our previous process required a lot of attention on the part of the technicians, and this lead to a lot of variation in the results. Now with the Dako CoverStainer, slides have a consistent quality, which makes it a lot easier.”

The launch of the Dako CoverStainer is part of the Dako strategy to be the preferred partner to the pathology laboratory. The addition of H&E staining to the Immunohistochemistry and Special Stains product lines, that Dako has mastered for more than four decades, allows Dako to become a complete staining partner.

Facts about the Dako CoverStainer
The Dako CoverStainer is an automated instrument transforming the H&E staining process by combining the entire process from baking through coverslipping to determine the patient’s first and most critical diagnosis of cancer. The Dako H&E solution combines the advanced Dako CoverStainer with Dako Ready-to-Use (RTU) Reagents and a Dako validated pre-optimized staining protocol. The Dako CoverStainer can process up to 240 H&E slides per hour and the first results in 46 minutes which makes it the fastest in its automated class.

AUSTIN, TX–(Marketwire – August 30, 2010) – Drummond Group Inc., the trusted software testing lab, is one of the first to be approved by the Health and Human Services, Office of the National Coordinator for Health IT (ONC) to be an ONC-Authorized Testing and Certification Body (ONC-ATCB) to certify Complete EHRs and all EHR Modules for both ambulatory and inpatient settings. Eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) participating in Medicare and Medicaid programs to collect incentive payments through meaningful use of electronic health record (EHR) technology must use EHR technology certified by an ONC-ATCB.

“Drummond Group has been working diligently for many months to meet the stringent criteria set forth by ONC to become certified as an ONC-ATCB, and we are very pleased that ONC has recognized our efforts and our competency to be an approved testing and certification body,” says Rik Drummond, CEO Drummond Group Inc. “We are pleased to offer over ten years of software testing and certification experience in other industries to Healthcare. After executing several pilots on existing EHR products and working with industry consultants, our organization is more than prepared to test and certify healthcare products.”

“The ONC accreditation is an acknowledgement that Drummond Group is fully qualified to meet the needs of EHR meaningful use stage one testing and certification. We highly commend the work of ONC and their accreditation process which tested the details of our testing and certification process and our industry knowledge. Having started new tests with other industries, we found this approval process to be the most demanding and the most thorough we have encountered. With our approval as an ONC-ATCB, EHR vendors and implementers can have full confidence in our testing and certification services, and we look forward to beginning testing with the many EHR software companies that have contacted us.”

To learn more about Drummond Group’s EHR testing and certification program including test registration and related pricing, please visit: http://www.drummondgroup.com/

For more information on ONC’s ATCB program, please visit: http://healthit.hhs.gov/

About Drummond Group
Drummond Group Inc. (DGI) is the trusted test lab which works with standards groups, software/firmware vendors and industry groups to drive adoption of standards by offering global interoperability, conformance testing and certification. DGI facilitates these testing services under association-branded certification programs and its own Drummond Certified® program. Founded in 1999, DGI also represents best-of-breed in strategic interoperability testing recognizing the challenges of interoperability for industry over the product life cycle.

• DGI provides interoperability certification for M2M or business-to-business (B2B) standards which are used for the Fortune 500 financial information flow, representing billions of dollars per year. Cyber security of data transfer is critically tested.
• DGI manages the KANTARA INITIATIVE Global Interoperability Test Program for Identity information exchange for the US government and the other global leaders in identity.
• DGI facilitates software audits of the Controlled Substance Ordering System (CSOS) software managed in compliance with the DEA regulations.
• Drummond Certified® software and firmware is required in RFPs around the globe to ensure seamless, secure, interoperable products which make implementation easy, thereby significantly reducing costs.
• DGI was recently awarded two Department of Energy stimulus funded Smart Grid demonstration projects. DGI’s role in both projects relates to the interoperability and certification of Smart Grid technology.

Click here to see all recent news from this company

SUWON, SOUTH KOREA–(Marketwire – August 30, 2010) – Neurotech Pharmaceuticals Co., Ltd. has begun dosing in the Phase 1 clinical testing of AAD-2004. AAD-2004 was developed as a dual function drug to remove free radicals and PGE₂, the key mediators of nerve injury in Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). The Phase 1 clinical trial was initiated to evaluate the safety, tolerability, and pharmacokinetics of AAD-2004 in healthy volunteers in April, 2010. The first two cohorts of the clinical study have been successfully completed without serious adverse events.

About FREE RADICALS AND PGE₂ IN NEURODEGENERTIVE DISEASES
Free radicals and PGE₂-mediated inflammation are expected to play a central role in the neurodegenerative process occurring in neurodegenerative diseases including AD, PD, and ALS. However, no drugs have been developed to prevent free radicals in the brain of AD, PD, and ALS due to poor blood-brain barrier permeability and adverse effects. Long-term use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) has been limited by the risk of cardiovascular infarction and thrombosis as well as gastrointestinal complications. Currently there are no FDA-approved drugs to protect nerve cells against toxic free radicals and inflammation evolving in the nervous system of patients with AD, PD, and ALS.

About AAD-2004
The scientific founders of Neurotech Pharmaceuticals discovered a novel chemical library on the premise that a single agent combining the anti-inflammatory attributes of aspirin with powerful anti-oxidant efficacy would constitute effective disease modifying therapeutics for nerve protection in neurodegenerative diseases, based on the additive/synergistic neuroprotective effects via compromising free radicals and inflammation. With leading supports via 21C Frontier R&D Program in Neuroscience from Ministry of Education, Science, and Technology, a National Drug Discovery Program from Ministry of Health and Welfare, and Ajou University in South Korea, Neurotech Pharmaceuticals launched an Anti-Alzheimer’s Drug discovery program. AAD-2004 was selected as a final drug candidate based upon safety and efficacy study in animal models of AD that improved cognitive function far better than antioxidants or NSAIDs as well as memantine, an FDA approved drug for the symptomatic treatment of AD. The therapeutic potential of AAD-2004 has been verified in animal models of ALS, PD, and major depression. Unlike conventional NSAIDs causing gastric damage, however, AAD-2004 did not produce gastric damage even at a dose 400-fold higher than maximally effective doses in animal models.

“While NASIDs cause gastric and cardiovascular risks by preventing production of prostaglandins PGI₂ as well as PGE₂ by inhibiting cyclooxygenases, AAD-2004 selectively prevents PGE₂ production as an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), the terminal isomerase catalyzing conversion of PGH₂ to PGE₂, at nanomolar concentrations, which explains why AAD-2004 is safer than NSAIDs. In addition, the potent spin trapping property of AAD-2004 provides additional efficacy and safety,” said Byoung J. Gwag, Ph.D., CEO of Neurotech Pharmaceuticals and Professor at Department of Pharmacology of Ajou University School of Medicine. “The marked safety and efficacy in preclinical studies make AAD-2004 a promising drug candidate to advance into clinical trials. We are so pleased to see safety profile of AAD-2004 in human healthy volunteers exposed to doses higher than maximally effective doses in preclinical studies.”

About Neurotech Pharmaceuticals
Neurotech Pharmaceuticals was founded to develop drugs for the treatment of neurological diseases on the basis of the close collaboration of basic and clinical academic teams in 1998. In addition to AAD-2004, Neu2000, a moderate NMDA receptor NR2B-selective antagonist and potent antioxidant, has been developed as a drug candidate for stroke, spinal cord injury, acute myocardial infarction, and burn injury. Nonclincial and human phase I studies in the United States demonstrate that Neu2000 is safe (therapeutic index = 35 – 800 depending on types and severity of diseases) and thus can be advanced into human phase II study. ND-07 has been developed to treat inflammatory diseases including pancreatitis, inflammatory bowel disease, rheumatoid arthritis, and pain and is near the end of preclinical study.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Aug. 30, 2010) – Sunnybrook Health Sciences Centre will offer people a sneak peak of its greatly anticipated, new birthing facilities and neonatal intensive care units. Sunnybrook’s new facilities encompass more than 120,000 sq. ft. of space making it one of the largest and most comprehensive facilities of its kind in Canada. The Women & Babies Program will deliver 4,250 babies every year in this new space and will care for 1 of every 5 babies born in Ontario who weigh less than 3 pounds.

WAYNE, PA–(Marketwire – August 30, 2010) –  The Clinical and Laboratory Standards Institute (CLSI) and Association of Public Health Laboratories (APHL) are offering a teleconference to the health care community to learn more about the different considerations surrounding acceptance criteria on point-of-care (POC) glucose devices. The teleconference on September 30 is titled “POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor.”

The US Food and Drug Administration (FDA) recently held a public forum on glucose meter devices to gather wide perspectives on the clinical requirements for blood glucose meter accuracy and precision. Using the CLSI consensus process in gathering balanced viewpoints from industry, professional societies, and government bodies, this educational program will provide an overview of different perspectives surrounding the glucose device acceptance criteria for both self-testing and professional use, and possibly expand the presentations at the most recent FDA public meeting.

“This teleconference will not only highlight the need for glucose meter accuracy and precision, but also discuss the studies that have been performed and what is to come from the many organizations and associations looking into guidelines around this issue,” said Marcy Anderson, MS, MT(ASCP), Director of Development and Education, CLSI.

The teleconference will help participants to describe differences in the use of glucose meters in self-testing vs hospital or professional settings. They will also understand the differences between the perspectives of the government agency, professional expert, and POC glucose vendor representative. There will be an opportunity to ask questions at the end of the program.

Speakers include:

• Alan Cariski, MD, JD
  VP, Worldwide Medical Affairs, LifeScan Inc., Milpitas, California

• Courtney Harper, PhD
  Director, FDA Division of Chemistry and Toxicology Devices, Silver Spring, Maryland

• Mitch Scott, PhD
  Director, Division of Laboratory Medicine at Washington University Hospital, St. Louis, Missouri

Upcoming point-of-care teleconferences:

• Deciding Factor: Selection Criteria for Point-of-Care Testing Devices (588-614-10)
  September 16 • 1:00-2:00 PM Eastern (US) Time

• POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor (588-623-10)
  September 30 • 1:00-2:30 PM Eastern (US) Time (1.5 contact hours)

• Getting It Right: Approaches to Reducing Errors at the Point of Care (588-616-10)
  October 7 • 1:00-2:00 PM Eastern (US) Time

Register for the upcoming teleconferences at www.aphl.org/clsi. Discounts are offered for conference series registration.

APHL is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) P.A.C.E.^® Program. Participants will be awarded contact hours for each program they successfully complete. P.A.C.E.^® is accepted by all licensure states except Florida. Florida continuing education credit will also be offered.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information on CLSI, visit the CLSI website at www.clsi.org or call 610.688.0100.

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – August 30, 2010) –  Catholic Healthcare West (CHW), the nation’s eighth largest health system, today announced that its severe sepsis prevention initiative has saved an additional 991 lives and reduced severe sepsis inpatient mortality rate by 33 percent at the end of three years.

“A core tenant of the health care reform plan enacted by Congress is that we can improve quality while also reducing costs,” says Lloyd H. Dean, CHW President/Chief Executive Officer. “The results of this program clearly demonstrate those achievements are possible.”

CHW launched the three-year initiative in July 2007 with the goal of reducing its inpatient severe sepsis mortality rate by five percent across its 41 hospitals in California, Arizona, and Nevada by 2010.

“This is a remarkable expression of CHW’s mission to deliver excellent care,” says Robert Wiebe, MD, CHW’s Chief Medical Officer. “The collaborative effort amongst our outstanding physicians, nurses, and hospital staff has shown tangible improvements in care. We are diagnosing sepsis earlier, treating it more aggressively, and saving lives.”

Sepsis is the body’s overwhelming response to a serious bacterial infection. It can start in a single area in the body or can be widespread in the bloodstream. If not diagnosed early and treated quickly, sepsis can rapidly lead to organ failure and death. According to the national Surviving Sepsis Campaign, there are more than 750,000 cases of severe sepsis annually in North America with 210,000 fatalities, making it the number one cause of inpatient mortality.

Using the Surviving Sepsis Campaign recommendations, as well as the Institute for Health Care Improvement’s collaborative improvement methods, CHW caregivers and staff focused on early recognition of severe sepsis patients, increasing the use of aggressive and appropriate treatment protocols, educating healthcare professionals, monitoring compliance to treatment guidelines, and facilitating data collection for the purposes of improvement and feedback.

“This is innovative and groundbreaking work,” said R. Phillip Dellinger, M.D., a leader in the Surviving Sepsis Campaign, professor of medicine at University Medicine and Dentistry in New Jersey, and the director of critical care for Cooper University Hospital in Camden, New Jersey. “CHW’s caregivers have demonstrated the power of a well-organized quality program that both reduces morbidity and mortality while also achieving significant cost savings.”

Each CHW hospital has a multi-disciplinary team comprising physicians, nurses, respiratory therapists, pharmacists, and other clinicians that implement an early resuscitation ‘bundle’ — a series of evidence-based measurable treatments that have proven effective when implemented together — during the first six hours a patient is diagnosed with sepsis. The bundle consists of measuring the patient’s blood lactate levels and blood cultures, administering appropriate antibiotics within the first hour of a patient presenting to the emergency department and administering appropriate treatments for low blood pressure. 

Because sepsis is such a widespread and serious problem in the inpatient setting, studies have shown that treating it more effectively will result in lower health care costs. In three years, CHW estimates its severe sepsis prevention resulted in a savings of more than 36 million in direct variable costs.

“By standardizing this early resuscitation bundle throughout our system, CHW is able to deliver the appropriate care to our patients when they need it, avoiding lengthy and costly hospital stays,” says Dr. Wiebe.

In its nine Sacramento and San Francisco Bay Area hospitals, CHW has received a two-year grant totaling $1.8 million from the Gordon and Betty Moore Foundation to support the expansion of sepsis prevention nursing education. Utilizing the grant and a portion of matching funds, CHW has hired an analyst, paid for innovative sepsis education services and has developed a comprehensive sepsis education program.

“The Gordon and Betty Moore Foundation is pleased to be supporting this important initiative, which has made a significant and positive impact on the lives of patients and their families,” said Marybeth Sharpe, Betty Irene Moore Nursing Initiative Program Director. “We congratulate the CHW hospitals on implementing evidence-based practices for identification and treatment of sepsis and recognize the critical role of CHW’s frontline nurses and other clinicians in this effort.”

About Catholic Healthcare West
Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and the largest not-for-profit hospital provider in the West. Founded in 1986, the CHW network of more than 10,000 physicians and approximately 54,000 employees serve a population spanning 22 million people at 41 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In 2009, CHW provided $1.2 billion in charity care, community benefits, and unreimbursed patient care. For more information, please visit our website at www.chwHEALTH.org.

TAMPA, FL–(Marketwire – August 30, 2010) –  Sage North America today announced that its Sage Healthcare Division has released Sage Intergy version 6.10 and the new Sage Intergy Meaningful Use Edition. This Sage Intergy Meaningful Use Edition features the components required for physicians to be eligible for federal electronic health records (EHR) incentives, a key provision of the 2009 American Reinvestment and Recovery Act of 2009 (ARRA). 

Under ARRA, physicians and other eligible professionals may qualify for bonus payments from Medicare and Medicaid in exchange for demonstrating “meaningful use” or a certified EHR system.

Sage Intergy is a synergistic clinical, financial and administrative solution that helps physicians to improve the quality and efficiency of care they deliver. The Sage Intergy family of products includes integrated practice management, electronic health records, clinical and business intelligence and tools for online patient engagement. Providers can access Sage Intergy from multiple practice locations, from home, or other remote locations either through a central patient database server, or as a Sage-hosted solution on a monthly subscription basis. 

Sage Intergy Version 6.10 includes enhancements designed to meet key industry certifications, such as the CCHIT 2011 Ambulatory EHR certification and upcoming meaningful use certification. The Meaningful Use Edition expands on the core functionality in v6.10 by providing physicians with additional tools for patient engagement and meaningful use reporting.

“In this combined release, Sage is introducing exciting and innovative solutions that will not only help our customers take full advantage of stimulus dollars, but also greatly enhance the practice experience for patients and physicians,” said Tony Ryzinski, Senior Vice President of Marketing and Product Management with Sage.

Most significant in this latest Sage Intergy release is a new “MU dashboards” feature. This user-friendly analysis tool is used by providers and practices to track performance against clinical quality measures included in the meaningful use guidelines (such as the percentage diabetic of patients with a hemoglobin A1C of less than or equal to 7 percent). The MU dashboards also allow providers to scorecard performance against indicators that measure how they use the system in relation to the meaningful use criteria (for example, for what percentage of patients they maintain an active problem list).

Version 6.10 also includes enhancements designed to further refine interoperability between Sage Intergy and health information exchanges. Expanding on the already considerable list of online services available to patients from the Sage Intergy Practice Portal, Sage has added the ability for patients to view statements and pay bills online and receive secure health reminders from their providers.

Ryzinski said Sage will be ready for meaningful use certification “as soon as a certification body is announced.”

“Once our industry gets past this crucial milestone, it will become increasingly important for healthcare providers and technology vendors alike to understand the broader context of meaningful use,” said Ryzinski. “Stimulus dollars are only an incentive to help providers acquire the technology needed to continue their work to transform healthcare and, ultimately, improve healthcare outcomes for patients while creating practice efficiencies. Federal healthcare reform will drive the meaningful adoption of technology and in turn, should allow physicians to refocus on providing care and improving lives through delivery of care in a time when they are constantly forced to meet non-care demands on their time.”

View Sage Healthcare Division YouTube interviews.
View Sage Healthcare Division information.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

RESEARCH TRIANGLE PARK, NC–(Marketwire – August 30, 2010) –  Patient recruitment is not the first step in a clinical trial, but well-designed recruiting could be the most important piece. Companies have only scratched the surface of the potential benefits of deep patient understanding to more accurately develop protocols that will meet enrollment targets, according to consulting firm Cutting Edge Information.

According to the upcoming study, “Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs,” 72% of respondents perform pre-project research into patient emotion and motivation. But much of that research is ‘surface deep,’ according to industry participants.

“The more information trial designers have about the patient population, the more likely you are to design a study that meets all enrollment goals,” said Jason Richardson, president of Cutting Edge Information. “More nuanced demographic research saves dollars as coordinators put limited funds into the right recruiting channels.”

Project partners pointed to geographically focused recruitment as a significant potential advantage in patient enrollment. Identifying patient clusters aids in clinical site management, helps determine ideal patient incentives and lets the clinical team communicate directly with local advocacy groups.

Thinking like a patient means heavily weighing emotional motivators. Benchmarking partners mentioned common considerations including:

• Are patients embarrassed by their condition?
• Will daily office visits be too painful a reminder that they are living with the disease?
• Will they feel altruistic in joining a study?
• Will the opportunity to increase the scientific understanding of a disease resonate with them?

More experienced patient recruitment specialists are better prepared for such issues, the study suggests. A clinical trial team may push for additional office visits, for example, while a recruitment specialist can identify the point at which site visit frequency will increase drop-out rates. In such situations, the team can identify the best trial protocols to meet the needs of all stakeholders.

“Knowing your patient volunteers and making a strong effort to think like them ultimately helps teams better meet the many challenges of study recruitment,” added Richardson.

Cutting Edge Information (http://www.cuttingedgeinfo.com/) is a consulting firm serving the life science industry. For more information about clinical trials management, contact Elio Evangelista at 919-433-0214 or [email protected]. For media information, contact Stephanie Swanson at 919-433-0212 or [email protected].

Click here to see all recent news from this company

MARKHAM, ONTARIO–(Marketwire – Aug. 30, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced the appointment of Margery Cunningham, CFA, to its Board of Trustees, effective immediately, for a term to expire at the next annual meeting of unitholders, whereupon Ms. Cunningham will stand for election.

Margery Cunningham brings with her invaluable experience as a highly regarded analyst within the health care sector. Ms. Cunningham was with Lehman Brothers for 11 years beginning in 1997, most recently as Managing Director and Global Head of Product Training, overseeing training for over 28,000 employees. Prior positions with Lehman Bothers included, Associate Director of Credit Research, responsible for managing, training and developing new analysts and associates in the Fixed Income Credit Research Department, and as a High Yield Bond Analyst. As an analyst, Ms. Cunningham was a perennial Institutional Investor magazine all-star analyst in the high yield health care category. Her research career has spanned more than 20 years, including both equity and fixed income research for firms such as Kidder, Peabody & Co., and Paine Webber.

“Extendicare REIT is delighted to welcome Ms. Cunningham to its Board of Trustees,” said Mel Rhinelander, Chairman of Extendicare REIT. “Ms. Cunningham will be a valuable board member providing input and guidance as we develop strategies to position Extendicare REIT for continued success. Along with the additions earlier this year of Governor Howard Dean and Ben Hutzel, we feel we have taken important steps to add depth to our Board of Trustees.”

Ms. Cunningham received her A.B. in Applied Mathematics from Harvard University in 1980, and went on to receive an M.S. in Management with a concentration in Finance and Economics from the Sloan School of Management, Massachusetts Institute of Technology, in 1982. As well, she is a Chartered Financial Analyst.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,800 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 263 senior care centers in North America have capacity for approximately 29,200 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

SAN FRANCISCO, CA–(Marketwire – August 30, 2010) –  Today at VMworld 2010, QuorumLabs (www.QuorumLabs.com) announced a new release of the onQ Business Continuity Appliance that doubles previous performance and capacity. onQ 2.2 provides one-click instant recovery for up to 25 physical and virtual servers per appliance, and can scale to any number of servers using multiple appliances.

Unlike traditional multi-product enterprise solutions, onQ is a simple, turnkey appliance that pre-integrates a number of sophisticated technologies — such as replication, deduplication, snapshots & continual virtualization — into a single box. onQ automatically maintains and manages up-to-date virtual machine clones on a bare metal hypervisor to give companies high performance instant recovery in the event of a failure without requiring any additional hardware or software. onQ goes beyond off-site and on-line backup and makes complete business continuity easy and affordable — without the complexity, cost, or lengthy deployment projects required of traditional enterprise solutions.

“To provide an equivalent solution to what QuorumLabs has packaged into a single appliance requires a high level of engineering and an extended migration and integration project,” said Bob Boyer, chief marketing officer, Transcend United. “For small and mid-sized companies who need business continuity, this has been a barrier to deploying virtualization-based solutions since they don’t have the in-house expertise or the time. It’s a lot to tackle. That’s where onQ fits in: an easy to implement, easy to maintain and easy to test appliance.”

Price and Availability

QuorumLabs’ partners offer onQ in a variety of ways to meet customer needs, including via managed services, or dual-appliance configurations with up to 13 terabytes internal storage (expandable with external storage) starting at under $15,000 for a pair of replicating appliances. Visit www.QuorumLabs.com to find your local reseller.

About QuorumLabs

QuorumLabs™ develops technologies and products that make enterprise-class technologies such as virtualization easy and affordable for small and medium-sized businesses. QuorumLabs introduced the industry’s first turnkey business continuity solution that ensures One-Click Recovery™. Located in Fremont, California, QuorumLabs was spun out of Themis Computer in 2008. More information about QuorumLabs can be found at www.QuorumLabs.com.

QuorumLabs, onQ, One-Click Recovery, and the QuorumLabs logo are trademarks of QuorumLabs, Inc. in the United States and other countries.

MUNDELEIN, IL–(Marketwire – August 27, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, today introduced a new CMS Survey Readiness Program for ambulatory surgery centers (ASCs). The program helps ASCs in interpreting new Centers for Medicare and Medicaid Services (CMS) regulatory requirements, preparing for the CMS survey and improving patient safety. CMS recently mandated the new survey process to promote better infection control practices within the estimated 5,300 freestanding ambulatory surgery centers nationwide that account for 53.3 million same-day surgical and non-surgical procedures.

“With more invasive diagnostic and surgical procedures being performed in outpatient settings, CMS has turned its attention to the surgery center market,” said Dirk Benson, Medline’s Vice President of Sales, Ambulatory Surgery Division. “This fast-paced, high-volume environment provides unique challenges and opportunities for infection control and prevention. Medline’s CMS Survey Readiness Program combines educational opportunities, readiness tools and useful resources to help ASCs maintain compliance and retain financial reimbursement for the services they provide.”

Medline’s CMS Readiness Program consists of a series of modules, each designed to address a specific CMS regulation within the survey. The modules are written materials that accompany a series of webinars that ASC staff can attend to prepare for the surveys. Module one, Infection Prevention, is currently available through Medline University (www.medlineuniversity.com), Medline’s free online educational resource. Upcoming modules include: Environmental Compliance of Ambulatory Surgery; Crafting a Quality Assessment Improvement Program; Rules and Regulations for Governing Boards; and Understanding Patient Rights, Admission and Discharge Needs. 

The first webinar, Keys to Successful Ambulatory Surgery Center Surveys, is currently available on Medline University and free to all surgery centers. Participants will learn how to use the program and how the modules will prepare the facility for the survey. At the conclusion of the program, ASCs will have the tools and resources to improve patient safety; pass a CMS survey; potentially prevent interruption in patient care and lost revenue; and reduce staff anxiety and work load by providing a “turn key” program. 

For more information on Medline’s CMS Survey Readiness Program for Ambulatory Surgery Centers visit www.medline.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

NEW YORK, NY–(Marketwire – August 27, 2010) –  The economy of Mexico is challenged by a recession, oil prices, and a falling exchange rate. Yet according to a new report from healthcare market research publisher Kalorama Information, Mexico is still attracting clinical diagnostic companies and showing modest growth. Mexico’s IVD market grew 75% between 2004 and 2009, according to the report “McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico,” which is a joint publication of Kalorama and emerging IVD market research firm McEvoy and Farmer.

Mexico followed the United States into recession, which has hurt the private side of the in vitro diagnostic market, according to the report. Most diagnostic tests in Mexico are publicly-funded, but the report notes there may be a strain on finances next year due to the fall in the price of oil and an impending budget deficit. The exchange rate has changed from 10.9 pesos per dollar in 2007 to the current level of nearly 13; a sixteen-percent decline over the past two years. 

“The fall of the peso hurts because most IVD products are not manufactured in Mexico,” said Bruce Carlson, Publisher of Kalorama Information. “Still, the analysts see a good number of top-level manufacturers here, and they are betting that when the US comes out of recession, Mexico will follow.”

In the report, Kalorama Information and McEvoy and Farmer detail 18 manufacturers and 30 distributors that are currently competing in Mexico’s IVD market, including Abbott, BD and Bio-Rad.

“McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico” provides more information, including healthcare statistics, market size numbers for segments of the IVD market and information about distributors and what products they distribute in Mexico. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79516&productid=2768446

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

RENO, NV–(Marketwire – August 27, 2010) – PPJ Enterprise (PPJ) (PINKSHEETS: PPJE) (“The Company”), a leader in proprietary automated health care reimbursement cycle (all specialties), online health information digital systems and practice information management digital system software for health care and general businesses worldwide, has announced that its subsidiary, Professional Billing Service (PBS), has exceeded its gross revenue over $85,000 during the first 26 days in August of 2010. The Company expects to end the month with gross revenue of $90,000 to $100,000 with the knowledge of pending checks on the way.

Company’s expectation of revenue was delayed due to some unusual circumstances such as some of the large clients provided wrong Medicare PTAN (provider number), EIN number with wrong everything else and became adamant of the accuracy of the information. None of the insurance company and Medicare could recognize those clients to issue payments. Most of the issues have been resolved and checks are being issued to those clients now.

“I like to inform our shareholders that we have worked relentlessly through very difficult situations by keeping their interests in our heart and now I am very pleased to stat that we are on our way to the next level” — Noted by our CEO, Ms. Basu.

Company employees specially few of them barely got any decent payments as compensation but took a chance with the Company. Ms. Basu, our CEO, has been paid almost nothing during the last three years. She has taken a huge hit personally but never felt discouraged about this company and its abilities to rise again.

“I sincerely thank all of our shareholders who have placed their faith in us and stayed with us in our difficult days” — CEO, Ms. Basu.

The company also reports resolution of the following issues:

1. Company is in “Active” status with Nevada Secretary of State.

2. Attorney Mr. Michael Morey of Las Vegas has been retained to provide “Attorney Letter” to Pinksheets.com. Per Pinksheets.com they are good to work with Mr. Morey. Ms. Basu personally met with Mr. Morey and provided documentation of billing service, software and claims of company assets. Mr. Morey is currently working on all documents and expects to provide the required letter to Pinksheets.com within a very short period.

3. Financials have been posted. Company expects to update by 8/31/2010, 9/30/2010 and ongoing.

4. Highly experienced PR company being interviewed, company expects to keep its shareholders informed regularly as the company becomes “Current” with Pinksheets.com.

5. Highly technical and very experienced software developer has been retained to transfer our practice management, billing and electronic health record into portable touch pad technology to provide instant access to physicians of their patients data from anywhere using mobile technology.

For more information please contact: PPJ Enterprise Management at (775) 348-5735, website: http://www.ppjenterprise.com/, email: [email protected].

Forward-Looking Statements

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This press release contains or may contain forward-looking statements such as statements regarding the Company’s growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risk and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.”

NEW YORK, NY–(Marketwire – August 27, 2010) –  Corporate Profile’s financial website www.CPreports.com announces Ray Dirks Research’s recommendation of Cleveland BioLabs, Inc. (NASDAQ: CBLI). 

In the report, Ray expects Cleveland BioLabs’s shares to move higher based upon upcoming inflection points, with a one-year price target of $15.

About CPreports.com
CPReports.com features Gene Marcial, Ray Dirks and Goldman Small Cap Research. The website and newsletter provide readers and subscribers fresh, original, and highly informative ideas and market commentary that they won’t get anywhere else. Content is focused on what is going on in the stock market and on Wall Street, including stories about large-capitalization as well as small-cap companies, both on the long and short side.

About Corporate Profile.com
www.CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for today’s hottest tips and market info.

About Ray Dirks Research
Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high-net worth investors both in the U.S. and internationally. Ray’s research includes Healthcare Stocks and Special Situations. Ray has written two books, “The Great Wall Street Scandal” and “Heads You Win, Tails You Win,” published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals. Ray can be reached at: [email protected] or 917-923-0487.

Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company’s actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectation.

POMONA, CA–(Marketwire – August 26, 2010) – Western University of Health Sciences is addressing California’s dire need for more health care workers thanks to visionary leadership, California State University Chancellor Charles Reed, EdD, said during his keynote address for the dedication of the Health Education Center and Patient Care Center on Aug. 25, 2010.

California is in a unique and precarious position today, Reed said. The state is growing by leaps and bounds, and it’s growing fastest among the underserved population that needs health care assistance. One recent economic study predicted that California needs to train an estimated one million workers for allied health careers by the year 2025 to care for California’s 49 million residents.

“The role of all universities, public and private, is to prepare students to meet the future needs of our businesses and communities and families, and in doing so, universities need to be fully integrated in their communities,” Reed said. “Here at Western University, community service has been a cornerstone of this university’s philosophy since it was first established more than 30 years ago. Today’s dedication represents another new chapter in the expansion of WesternU’s efforts to meet the needs of so many Californians.”

The Health Education Center provides much needed teaching space and is home to the cutting edge interprofessional education program. The Patient Care Center provides a living laboratory for students who are embarking on health care careers, Reed said.

“It has already proven to be an incredibly valuable health resource to members of the surrounding community,” he said.

Reed praised WesternU Founding President Philip Pumerantz for his long-term vision and for continuing to propel the university to new, greater heights.

“He also deserves credit for developing a real sense of family and community here at Western University,” Reed said. “The personal experience that students have here translates into the kind of experience that they can give their patients. And that is an incredibly important contribution to our society and to our state.”

Reed also acknowledged the contributions of WesternU Provost and COO Benjamin Cohen, Assistant Provost for Strategic Operations and Clinical Services Joan Sandell, Executive Director of Facilities and Physical Plant Todd Clark and WesternU board member Vince Naimoli, who he has known more than 20 years. In addition, Pumerantz thanked the Board of Trustees for its support and Senior Vice President for Advancement Thomas Fox for organizing the dedication ceremony.

“What Western University does so well is to prepare students in a range of health disciplines with a focus on comprehensive and compassionate care,” Reed said. “Thanks to the contributions of so many people and supporters here and not here, Western will now be able to do even more and better work on behalf of the students and the community and the state of California.”

Someone once asked if caring and science could exist at the same time in an academic setting, Pumerantz said.

“Humanism is a major part of the education and training of the health professions, and the best example of that is Western University of Health Sciences,” he said. “These buildings are very attractive, they’re state of the art, they’re beautiful, but the buildings don’t really tell you that this is the university. It’s what’s in the buildings that represent the university. It’s the people. It’s the philosophy. It’s the caring. That’s what’s in these buildings that make a difference.”

IRVINE, CA–(Marketwire – August 26, 2010) –  A partnership between the Cystinosis Research Foundation and the Cystinosis Foundation along with a collaboration of 12 advocate foundations from around the world has launched the first global cystinosis patient registry. The registry’s goal is to connect patients with researchers and others developing potential new treatments and a cure for the metabolic and fatal disorder that afflicts about 2,000 persons, mostly children, worldwide.

The purpose of the Cure Cystinosis International Registry is to identify people with cystinosis worldwide and collect their medical histories and information. This information will allow clinicians, researchers and pharmaceutical companies to accelerate novel treatments and a cure for cystinosis.

“The cystinosis community has experienced exciting scientific advancements to treat and cure cystinosis. Currently there is a proliferation of research activity, breakthroughs and hope. The CCIR is a central hub of information and will be used as a resource for the research community to advance the care and treatment for those with cystinosis,” said Nancy Stack, President of the Cystinosis Research Foundation.

The CCIR is the only registry created specifically for individuals with cystinosis and will contain current information regarding cystinosis clinical trials and studies. All patient information is de-identified (anonymous) and held in a secure data base accessible only by the CCIR curator. Information that could identify participants and their family members will not be shared without their expressed written approval. Participants will also be able to view aggregate data allowing them to view how they fit within the larger cystinosis community.

The registry was formed following discussions among leaders in the cystinosis community who saw the need to establish a comprehensive resource to connect and serve the needs of the entire cystinosis community. The CCIR’s organizers come from family foundations and the international cystinosis academic and scientific communities. These groups are focused on the need to accelerate the research process in the quest to find the cure for cystinosis.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of one of the compartments of the cell. Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

CCIR officials say recruitment for clinical trials can be a lengthy process, especially for a rare disease like cystinosis. Participation in this registry will help speed up the recruitment process and facilitate and expedite clinical trials, officials said.

Plans are to offer the website in French, Italian and Spanish following the launch.

One of the major features of the registry is a professional/researcher portal that will allow the scientific and pharmaceutical communities to request access to de-identified patient information. Those seeking patient information have to meet stringent requirements governing patient medical data, including patient approval. Each request will be reviewed by the CCIR curator and operations board.

Twelve other cystinosis foundations have joined as advocates of the CCIR. They are: the Cystinosis Awareness & Research Effort in Canada; the Australian Cystinosis Support Group; Cystinosis France, Cystinosis Foundation UK; Cystinosis Ireland; The Cystinosis Foundation, New Jersey Chapter; Cystinosis Support Group South Africa; 24 Hours for Hank; Hope For Holt; Jenna & Patrick’s Foundation Of Hope; Joshua’s Journey of Hope; and Tina’s Hope for a Cure.

For more information about Cure Cystinosis International Registry and the Cystinosis Research Foundation of Irvine, Calif., contact Zoe Solsby at (949) 223-7610 or visit www.cystinosisregistry.org or www.cystinosisresearch.org.